GlassScriptPhysician profile
Caroline Day
NPI 1144467309
$8,956.63
in general payments reported to CMS, 2019-2025
44 companies · $1,246 in 2025
The $1,246 reported for 2025 was more than what 89% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $1,229 · 2021: $1,607 · 2022: $1,248 · 2023: $1,097 · 2024: $1,147 · 2025: $1,246.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,478 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13.10.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,477.50 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,974.61 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,151.28 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $650.29 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $592.16 | 2019-2025 | |
| Lilly USA, LLC | $567.87 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Takeda Pharmaceuticals U.S.A., INC. | $428.16 | 2019-2025 | Trintellix |
| Allergan, INC. | $422.73 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $386.95 | 2019-2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $379.96 | 2019-2025 | Jardiance |
| Biohaven Pharmaceutical Holding Company LTD. | $299.70 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $276.14 | 2019-2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $180.00 | 2019-2024 | Airsupra, Farxiga |
| Ibsa Pharma INC. | $151.35 | 2019-2025 | Licart, Tirosint, Tirosint |
| Corium, LLC | $145.83 | 2023-2025 | Azstarys |
| Janssen Pharmaceuticals, INC | $142.17 | 2019-2021 |
Show all 44 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Caroline Day listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.